Advertisement

Epstein-Barr-Virusinfektionen

  • V. Schuster
Part of the HNO Praxis Heute book series (HNO, volume 15)

Zusammenfassung

Das Epstein-Barr-Virus (EBV) gehört neben dem Herpes-simplex- (HSV), dem Varicella-Zoster-(VZV), dem Zytomegalievirus (CMV) und den humanen Herpesviren Typ 6 (HHV 6) und Typ 7 (HHV 7) zur Gruppe der menschlichen Herpesviren. EBV wurde erst 1964 mit dem Elektronenmikroskop in Tumorzellen des endemischen Burkitt-Lymphoms (BL) entdeckt (Epstein et al. 1964), wenige Jahre später gelang dem Ehepaar Gertrude und Werner Henle der Nachweis, daß EBV der Erreger der infektiösen Mononukleose ist: Ein Mitarbeiter entwickelte bei Laborar-beiten die Symptome einer Mononukleose, in seinem Blut fand sich eine Serokonversion von EBV-Antikörpern, aus peripheren Lymphozyten des Patienten ließ sich eine spontane (EBV-positive) B-Zellinie etablieren (Henle et al. 1968). Diese Beobachtungen wurden später von mehreren Arbeitsgruppen bestätigt (Evans 1974). Die klinische Symptomatik der infektiösen Mononukleose (Fieber, Lymphadenopathie, Angina, Organomegalie, Exanthem) wurde bereits vor über 100 Jahren unabhängig von-einander durch die 2 Forscher Filatow (1885) und Pfeiffer (1889) beschrieben. Pfeiffer nannte die Erkrankung Drüsenfieber. 1920 wurde von Sprunt u. Evans die heute allgemein übliche Bezeichnung infektiöse Mononukleose eingeführt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Andersson J, Britton S, Ernberg I et al. (1986) Effect of acyclovir on infectious mononucleosis: a double-blind, placebo-controlled study. J Infect Dis 153:283–290PubMedCrossRefGoogle Scholar
  2. Brook I, de Leyva F (1994) Microbiology of tonsillar surfaces in infectious mononucleosis. Arch Pediatr Adolesc Med 148:171–173PubMedCrossRefGoogle Scholar
  3. Epstein MA, Achong BG, Barr YM (1964) Virus particles in cultured lympho blasts from Burkitt’s malignant lymphoma. Lancet 1:252–253PubMedCrossRefGoogle Scholar
  4. Filatow NJ (1885)/(1942) Lectures on acute infectious diseases of children. Acta Med Scand 133 (Suppl): 1–102Google Scholar
  5. Fisher A, Blanche S, Le Bidois J et al. (1991) Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 324:1451–1456CrossRefGoogle Scholar
  6. Fujisaki T, Nagafuchi S, Okamura T (1993) Gamma-interferon for severe chronic active Epstein-Barr virus. Ann Intern Med 118:474–475PubMedGoogle Scholar
  7. Greenspan JS, Greenspan D, Lennette ET et al. (1985) Replication of Epstein- Barr virus within the epithelial cells of oral “hairy” leukoplakia, an AIDS-associated lesion. N Engl J Med 313:1564–1571PubMedCrossRefGoogle Scholar
  8. Gu SY, Huang TM, Ruan L et al. (1993) On the first EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. In: The Epstein-Barr virus and associated diseases (Eds. T. Tursz, J. S. Pagano, D. V. Ablashi et al.) INSERM/John Libbey Eurotext Ltd, 1993, pp 579–584Google Scholar
  9. Hanto DW, Frizzera G, Gajl-Peczalska KJ, Simmons RL (1985) Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation 39:461–472PubMedCrossRefGoogle Scholar
  10. Henle G, Henle W, Deihl V (1968) Relation of Burkitt’s tumor associated herpes- type virus to infectious mononucleosis. Proc Natl Acad Sci USA 59:94–101PubMedCrossRefGoogle Scholar
  11. Herbst H, Niedobitek G, Kneba M et al. (1990) High incidence of Epstein-Barr virus genomes in Hodgkin’s disease. Am J Pathol 137:13–18PubMedGoogle Scholar
  12. von der Horst C, Joncas J, Ahronheim G et al. (1991) Lack of effect of peroral acyclovir for the treatment of infectious mononucleosis. J Infect Dis 164:788–792PubMedCrossRefGoogle Scholar
  13. Kamel OW, van de Rijn M, Weiss LM et al. (1993) Reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 328:1317–1321PubMedCrossRefGoogle Scholar
  14. Kawa-Ha K, Franco E, Doi S et al. (1987) Successful treatment of chronic active Epstein-Barr virus infection with recombinant interleukin-2. Lancet II: 154CrossRefGoogle Scholar
  15. Klein G (1994) Epstein-Barr virus strategy in normal and neoplastic B cells. Cell 77:79–93CrossRefGoogle Scholar
  16. Lumio J, Karjalainen S (1993) Patients treated in hospital for infectious mononucleosis and risk of cancer. Scand J Infect Dis 25:283–288PubMedCrossRefGoogle Scholar
  17. Marklund G, Lundberg C, Nord CE, Ernberg I (1986) Evidence of tinidazole interference in the oropharyngeal inflammatory process during infectious mononucleosis. Scand J Infect Dis 18:503–510PubMedCrossRefGoogle Scholar
  18. Moss DJ, Misko IS, Burrows SR et al. (1988) Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants. Nature 331:719–721PubMedCrossRefGoogle Scholar
  19. Okano M, Matsumoto S, Osato T et al. (1991) Severe chronic active Epstein-Barr virus infection syndrome. Clin Microbiol Rev 4:129–135PubMedGoogle Scholar
  20. Okano M, Nakanishi M, Taguchi Y, Sakiyama Y, Matsumoto S (1992) Primary immunodeficiency diseases and Epstein-Barr virus-induced lymphoproliferative disorders. Acta Paediatr Jpn 34:385–392PubMedGoogle Scholar
  21. Papadopoulos EB, Ladanyi M, Emanuel D et al. (1994) Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 330:1185–1191PubMedCrossRefGoogle Scholar
  22. Paul JR, Bunnell WW (1932) The presence of heterophile antibodies in infectious mononucleosis. Am J Med Sci 183:90–104CrossRefGoogle Scholar
  23. Pearson GR (1989) Infectious mononucleosis: The humoral response. In: Schlossberg D (ed) Infectious mononucleosis, 2nd edn. Springer, New York, pp 89–99Google Scholar
  24. Pfeiffer E (1889) Driisenfieber. Jahrb Kinderheilkd 29:257–264Google Scholar
  25. Porta G, Ramaiah N, Zucchi I et al.. (1992) Yac-based mapping of the XLP syndrome in the context of Xq24-q25. Cytogenet Cell Genet 58:2079–2080Google Scholar
  26. Pracher E, Grximayer-Panzer ER, Zoubek A, Peters C, Gadner H (1993) Bone marrow transplantation during fulminant EBV-infection in Duncan’s syndrome. Lancet II: 1362 (Letter)CrossRefGoogle Scholar
  27. Purtilo DT, Cassel CK, Yang JP, Harper R (1975) X-linked recessive progressive combined variable immunodeficiency (Duncan’s disease). Lancet I:935–940CrossRefGoogle Scholar
  28. Purtilo DT, Strobach RS, Okano M, Davis JR (1992) Epstein-Barr virus-associated lymphoproliferative disorders. Lab Invest 67:5–23PubMedGoogle Scholar
  29. Sauerbrei A, Sprossig M, Wutzler P, etal. (1983) Antibody formation against specific Epstein-Barr virus antigens in infectious mononucleosis with tonsillectomy in the acute phase of the disease. Laryngol Rhinol Otol 62:170–174CrossRefGoogle Scholar
  30. Schuster V (1993) Therapieversuche bei schweren chronisch aktiven EBV-Infektionen. Padiatr Praxis 45:731–732 (Letter)Google Scholar
  31. Schuster V (1994) Tonsillektomie und Epstein-Barr-Virusinfektionen. Tägl Prax 35:326–327Google Scholar
  32. Schuster V, Kreth HW (1992a) Epstein-Barr virus infection and associated diseases in children. I. Pathogenesis, epidemiology and clinical aspects. Eur J Pediatr 151:718–725PubMedCrossRefGoogle Scholar
  33. Schuster V, Kreth HW (1992b) Epstein-Barr virus infection and associated diseases in children. II. Diagnostic and therapeutic strategies. Eur J Pediatr 151:794–798PubMedCrossRefGoogle Scholar
  34. Schuster V, Kreth HW, Müller-Hermelink HK et al. (1990) Epstein-Barr virus infection rapidly progressing to monoclonal lymphoproliferative disease in a child with selective immunodeficiency. Eur J Pediatr 150:48–53PubMedCrossRefGoogle Scholar
  35. Schuster V, Kreβ W, Friedrich W, Grimm T, Kreth HW (1993) X-linked lymphoproliferative disease: Detection of a paternally inherited mutation in a German family using haplotype analysis. Am J Dis Child 147:1303–1305PubMedGoogle Scholar
  36. Schuster V, Seidenspinner S, Grimm T, Kreβ W et al. (1994) Molecular genetic haplotype segregation studies in three families with X-linked lymphoproliferative disease. Eur J Pediatr 153:432–437PubMedCrossRefGoogle Scholar
  37. Schuster V, Grimm T, Kreβ W et al. (1995) Die X-chromosomal-rezessive lymphoproliferative Erkrankung (XLP): Molekulargenetische Untersuchungen. Klin Pädiatr, in pressGoogle Scholar
  38. Sculley TB, Apolloni A, Hurren L, Moss DJ, Cooper DA (1990) Coinfection with A- and B-type Epstein-Barr virus in human immunodeficiency virus-positive subjects. J Infect Dis 162:643–648PubMedCrossRefGoogle Scholar
  39. Seemayer TA, Grierson H, Pirruccello SJ et al. (1993) X-linked lymphoproliferative disease. Am J Dis Child 147:1242–1245PubMedGoogle Scholar
  40. Serraino D, Franceschi S, Talamini R, et al. (1991) Socio-economic indicators, infectious diseases and Hodgkin’s disease. Int J Cancer 47:352–357PubMedCrossRefGoogle Scholar
  41. Shapiro RS, Chauvenet A, McGuire W et al. (1988) Treatment of B-cell lymphoproliferative disorders with interferon alfa and intravenous gamma globulin. N Engl J Med 318:1334PubMedCrossRefGoogle Scholar
  42. Sixbey JW, Nedrud JG, Raab-Traub N, Hanes RA, Pagano JS (1984) Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med 310:1225–1230PubMedCrossRefGoogle Scholar
  43. Skare JC, Grierson HL, Sullivan JL et al. (1989) Linkage analysis of seven kindreds with the X-linked lymphoproliferative syndrome (XLP) confirms that the XLP locus is near DXS42 and DXS37. Hum Genet 82:354–358PubMedGoogle Scholar
  44. Sprunt TP, Evans FA (1920) Mononuclear leucocytosis in reaction to acute infections (infectious mononucleosis). Bull John Hopkins Hosp 31:410–417Google Scholar
  45. Starzl TE, Nalesnik MA, Porter KA et al. (1984) Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1:583–587PubMedCrossRefGoogle Scholar
  46. Straus SE, Cohen JI, Tosato G, Meier J (1993) NIH conference. Epstein-Barr virus infections: biology, pathogenesis, and management. Ann Intern Med 118:45–58PubMedGoogle Scholar
  47. Sumegi J, Li S, Li B et al. (1992) Characterization of the XLP locus with YAC clones and identification of new flanking markers. Am J Hum Genet 51: A402Google Scholar
  48. Tomkinson BE, Wagner DK, Nelson DL, Sullivan JL (1987) Activated lymphocytes during acute Epstein-Barr virus infection. J Immunol 139:3802–3807PubMedGoogle Scholar
  49. Tomkinson BE, Maziarz R, Sullivan JL (1989) Characterization of the T cell-mediated cellular cytotoxicity during acute infectious mononucleosis. J Immunol 143:660–670PubMedGoogle Scholar
  50. Vowels MR, Lam-Po-Tang R, Berdoukas V et al. (1993) Correction of X-linked lymphoproliferative disease by transplantation of cord-blood stem cells. N Engl J Med 329:1623–1625PubMedCrossRefGoogle Scholar
  51. Williams LL, Rooney CM, Conley E etal. (1993) Correction of Duncan’s syndrome by allogeneic bone marrow transplantation. Lancet 11:587–588CrossRefGoogle Scholar
  52. Zimber U, Adldinger HK, Lenoir GM et al. (1986) Geographical prevalence of two types of Epstein-Barr virus. Virology 154:56–66PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • V. Schuster

There are no affiliations available

Personalised recommendations